It will be important, in future research, to compare the effectiveness of glycemic control achieved by glucagon-like peptide-1 receptor agonists with that of sodium-glucose cotransporter-2 inhibitors, as sodium-glucose cotransporter-2 inhibitors are similarly recommended for people at high risk for cardiovascular disease, kidney disease, and heart failure.14 This evidence concerns the gene GLP1R and kidney disorder.